Placebo to MK-8507 clinical trials

A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily

This study is testing a new weekly pill for adults with HIV-1, who are already doing well on their current daily medication. It aims to see how safe and effective a switch to the new treatment is.